Fulgent Genetics (FRA:7F0) EPS without NRI: €-0.67 (TTM As of Mar. 2026)


FRA:7F0 Fulgent Genetics Inc FRA:7F0
64 GF Score
Price €18.10
GF Value €20.87
! 4 Warning Signs
View Full Analysis

What is Fulgent Genetics EPS without NRI?

Fulgent Genetics FRA:7F0 -0.55% 64 EPS without NRI is €-0.67 as of Mar. 2026. GuruFocus rates FRA:7F0 with a GF Score™ of 64/100 and a GF Value™ of €20.87. The stock has 4 warning signs investors should review. Among 162 Medical Diagnostics & Research companies, Fulgent Genetics ranks worse than 94.44% on this metric.

Fulgent Genetics's earnings per share without non-recurring items for the three months ended in Mar. 2026 was €-0.69. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.67.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -58.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Fulgent Genetics's EPS without NRI or its related term are showing as below:

FRA:7F0' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69.1   Med: 27.3   Max: 212.4
Current: -58.3

During the past 12 years, Fulgent Genetics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 212.40% per year. The lowest was -69.10% per year. And the median was 27.30% per year.

FRA:7F0's 3-Year EPS without NRI Growth Rate is ranked worse than
94.44% of 162 companies
in the Medical Diagnostics & Research industry
Industry Median: 10.75 vs FRA:7F0: -58.30

Fulgent Genetics's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.69. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-2.06.

Fulgent Genetics's EPS (Basic) for the three months ended in Mar. 2026 was €-0.69. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-2.06.


Fulgent Genetics  (FRA:7F0) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Fulgent Genetics EPS without NRI Related Terms


Fulgent Genetics EPS without NRI Historical Data

* Premium members only.

The historical data trend for Fulgent Genetics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fulgent Genetics EPS without NRI Chart

Fulgent Genetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.75 5.47 -0.38 0.47 0.36

Fulgent Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.34 0.06 -0.18 0.14 -0.69

FRA:7F0 vs MYGN, CSTL, BDSX: EPS without NRI Comparison

For the Diagnostics & Research subindustry, Fulgent Genetics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fulgent Genetics PE Ratio without NRI vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's PE Ratio without NRI falls into.


FRA:7F0
64GF Score
Fulgent Genetics Inc FRA:7F0
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fulgent Genetics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €-0.67 mean?
Fulgent Genetics (FRA:7F0) has a EPS without NRI of €-0.67 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Fulgent Genetics and its competitors. According to the industry distribution chart, Fulgent Genetics ranks #153 out of 162 companies in the Medical Diagnostics & Research industry, placing it in the top 94.4%.
Is Fulgent Genetics' EPS without NRI too high?
Fulgent Genetics' current EPS without NRI is €-0.67. Based on the distribution chart, Fulgent Genetics ranks #153 out of 162 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Fulgent Genetics has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' EPS without NRI compare to MYGN and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Fulgent Genetics ranks #153 out of 162 companies for EPS without NRI. This places Fulgent Genetics in the lower half of its industry. The industry median EPS without NRI is 10.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Diagnostics & Research company?
The median EPS without NRI among Medical Diagnostics & Research companies is 10.75, based on 162 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Fulgent Genetics and its competitors. For the Medical Diagnostics & Research industry, the median EPS without NRI is 10.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fulgent Genetics's current EPS without NRI is €-0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Fulgent Genetics (FRA:7F0) has a current EPS without NRI of €-0.67. The stock's GF Value™ is €20.87, compared to a current price of €18.10 — trading 13.3% below its estimated fair value. The current EPS without NRI is €-0.67. Fulgent Genetics' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Fulgent Genetics (FRA:7F0), the current EPS without NRI is €-0.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fulgent Genetics (FRA:7F0) Overvalued in 2026?

Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued. The current stock price of €18.10 is trading 13.3% below its estimated GF Value™ of €20.87.

Key valuation signals for FRA:7F0:

  • EPS without NRI: €-0.67
  • GF Value™: €20.87 vs. price of €18.10 (13.3% below fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the FRA:7F0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fulgent Genetics Business Description

Other Exchanges FLGT:USAFLGT:Mexico
Address 4399 Santa Anita Avenue, El Monte, CA, USA, 91731
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
64GF Score

Get the complete analysis for FRA:7F0

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.10
Price
€20.87
GF Value